Flash FinanceUS
After hours S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · GT Biopharma, Inc. (GTBP)

GT Biopharma regains Nasdaq minimum bid price compliance after stock closes above $1.00

Positive Impact 2 of 5 legal/regulatory Written later

GT Biopharma received notice from Nasdaq on September 22, 2026, that it has regained compliance with the $1.00 minimum bid price requirement for continued listing on the Nasdaq Capital Market. The company's common stock maintained a closing bid price above $1.00 for at least ten consecutive business days, which Nasdaq required. The regained compliance removes the risk of delisting that the company had faced under the earlier deadline of November 16, 2026.

Key points

  • Nasdaq notified GT Biopharma on September 22, 2026 that it regained compliance with the minimum bid price requirement.
  • The stock had closed below $1.00 for 30 consecutive business days, leading to a Nasdaq notice on November 20, 2025.
  • On May 20, 2026, Nasdaq granted an additional 180 calendar day compliance period, through November 16, 2026.
  • The company's common stock closed above $1.00 for at least ten consecutive business days to meet the standard.

The filing

CompanyGT Biopharma, Inc. (GTBP)
Form8-K, current report
Filed with the SECSep 25, 2026, 4:10 PM ET
Accession number0001493152-26-044309

Items reported: 8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:51 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on September 25, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.